**Figure 2. Overall survival in JQ1-treated MM.1S-luc orthotopic xenograft model.**
Kaplan-Meier plot of overall survival during the pre-specified study period of 36 days. Female SCID-beige mice with established MM.1S-luc orthotopic xenografts were randomized to daily IP injections of 50 mg/kg (+)-JQ1, 50 mg/kg (-)-JQ1, or vehicle control. Total number of mice (n= 12 for each group). Log-rank (Mantel-Cox) test of (+)-JQ1 treatment compared to vehicle control; uncorrected p = .024, a priori Bonferroni adjusted alpha level = .025; (Bonferroni corrected p = .047). Log-rank (Mantel-Cox) test of (+)-JQ1 compared to (-)-JQ1; uncorrected p = .093, a priori Bonferroni adjusted alpha level = .025; (Bonferroni corrected p = .187).
Access the [analysis script][1] for the statistical tests related to this figure. The script will call the [data][2] directly from the OSF.
**Figure 3. Tumor burden in JQ1-treated MM.1S-luc orthotopic xenograft model.**
Female SCID-beige mice were orthotopically xenografted after intravenous injection with MM.1S-luc cells. Following detection of established disease (diffusely engrafted in the skeleton with an increase in bioluminescence), mice were randomly assigned to receive daily IP injections of 50 mg/kg (+)-JQ1, 50 mg/kg (-)-JQ1, or vehicle control (VEH). The number of mice per condition at start of treatment (n=12 for each group) and at day 22 ((+)-JQ1 = 11, (-)-JQ1 = 9, Vehicle = 7). One-way ANOVA on a natural log transformed day 22 bioluminescence signal; *F*(2,24) = 1.126, *p* =.341. The pairwise contrast between (+)-JQ1 treatment and Vehicle (Fisher’s LSD test); *t*(24) = 1.303, *p* = .205 with *a priori* alpha level = .05. The pairwise contrast between (+)-JQ1 and (-)-JQ1 treatment (Fisher’s LSD test); *t*(24) = 1.221, *p* = .234 with a priori alpha level = .05.
Access the [analysis script][3] for the statistical tests related to this figure. The script will call the [data][4] directly from the OSF.
[1]: https://osf.io/3jnx8/
[2]: https://osf.io/qdbh3/
[3]: https://osf.io/jvepy/
[4]: https://osf.io/8xmr7/
